Frontier Science collaborated with the Breast International Group (BIG) on the ALTTO and Neo-ALTTO trials. These trials were built on the results from the successful HERA trial and aimed to study the benefit of adding Lapatinib to Herceptin® in both adjuvant and neo-adjuvant treatment regimens for breast cancer.

Frontier Science was responsible for randomisation, various aspects of project management, data quality control and for statistical programming and analysis. These trials involved participation of breast cancer trials groups and independent sites around the world, including North America. Neo-ALTTO reported its primary analysis in The Lancet in 2012 and ALTTO in the Journal of Clinical Oncology in 2015.  The trials have now completed their follow-up analyses and Frontier Science is collaborating in the write up of the 10 year follow-up results for both trials.

OTHER PROJECTS

HERA

HERA

The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>

EPoS

EPoS

The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had premalignant polyps identified and removed from the large bowel, in...

NordICC

NordICC

Colorectal cancer (CRC) is major burden in western countries which develops over a long time-interval from precursor lesions which exist in the colon. Colonoscopy can detect and remove the precursor lesions and may therefore be an effective intervention for the...

WORK WITH US

Frontier Science Scotland provides adaptable solutions across data management and biostatistics for clinical trials. To find out more, get in touch.

data management

biostatistics

quality